支气管切除症:从孤儿疾病到个性化治疗时代
G Oscullo1, J D Gomez-Olivas1, M A Martinez-Garcí1
1Servicio de Neumología e Instituto de Investigación La Fe (IISLAFE). Hospital Universitario y Politécnico La Fe, Valencia, Spain;, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III. Madrid, Spain.
概括
支气管切除症的研究正在迅速扩大,超越了感染和炎症. 新的策略包括呼吸道分泌,营养,理疗,运动和个性化药物,以获得更好的患者结果.
科学领域:
- 肺病学和呼吸系统医学
- 临床研究 临床研究
背景情况:
- 支气管切除病历史上被认为是一种孤儿疾病.
- 它现在是呼吸系统研究中的一个快速扩展的领域.
- 了解支气管切除症需要一个多学科的方法.
研究的目的:
- 为了突出支气管切除症研究的不断变化的景观.
- 强调需要全面的治疗策略.
- 讨论 bronchiectasis 的个性化医学的进展.
主要方法:
- 文献综述和当前研究趋势的综合.
- 对支气管切除症的多学科和多维方面的分析.
- 检查新兴的治疗目标和个性化医疗方法.
主要成果:
- 支气管切除症的研究已经取得了显著的进展.
- 治疗策略现在包括感染,炎症,呼吸道分泌,营养,物理治疗,炼和并发症管理.
- 目前正在开发疾病特异性药理学剂.
结论:
- 支气管切除症的治疗需要一种整体的方法,而不仅仅是感染和炎症.
- 个性化医疗是支气管病治疗的关键未来方向.
- 持续的研究对于改善患者护理和结果至关重要.
相关概念视频
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment
975
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
975
Prescription, Nonprescription and Orphan Drugs
1.3K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
522
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
522
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
557
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
557
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
578
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
578


